The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association

Drucker, Aaron M.; Wang, Annie; Li, Wenqing; Sevetson, Erika; Block, Julie; Qureshi, Abrar A.

doi:10.1016/j.jid.2016.07.012

Cited by 547 publications

(498 citation statements)

References 40 publications

Supporting

Mentioning

443

Contrasting

Unclassified

Order By: Relevance

“…It is estimated that AD affects approximately up to 20% of children [1] and 10% of adult [2]. Patients with AD, particularly in moderate-to-severe type, commonly suffer from significant sleep disturbance, depression and anxiety [140,141,142], which inflicts considerable psychological and socioeconomic burdens on patients and their families [143,144]. Clinical symptoms vary from almost subclinical to persistent disease with concomitant other allergic disorders including allergic rhinitis, asthma, and food allergy [145,146,147].…”

Section: Preclinical and Clinical Studies Of Mscs In Inflammatory mentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for Inflammatory Skin Diseases: Clinical Potential and Mode of Action

Shin

Kim

Choi

et al. 2017

IJMS

View full text Add to dashboard Cite

Inflammatory skin disorders that cause serious deterioration of the quality of life have become one of the major public concerns. Despite their significance, there is no fundamental cure to date. Mesenchymal stem cells (MSCs) possess unique immunomodulatory properties which make them a promising tool for the treatment of various inflammatory diseases. Our recent preclinical and clinical studies have shown that MSCs can be successfully used for the treatment of atopic dermatitis (AD), one of the major inflammatory skin diseases. This observation along with similar reports from other groups revealed the efficacy and underlying mechanisms of MSCs in inflammatory dermatosis. In addition, it has been proposed that cell priming or gene transduction can be novel strategies for the development of next-generation high-efficacy MSCs for treating inflammatory skin diseases. We discuss here existing evidence that demonstrates the regulatory properties of MSCs on immune responses under inflammatory conditions.

show abstract

Section: Preclinical and Clinical Studies Of Mscs In Inflammatory mentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for Inflammatory Skin Diseases: Clinical Potential and Mode of Action

Shin

Kim

Choi

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…16 2 The deviated immune response towards Th2-dominant responses with increased immunoglobulin E production and distinct inflammatory events leading to allergic reactions against a multitude of environmental allergens from the air or from foods. 26,[30][31][32][33][34] The actual degree of individual suffering in the single patient has so far not received adequate attention in scientific literature. 21,22 The disease goes along with a remarkable economic burden both for the affected individual and for society and with marked impairment in quality of life.…”

Section: Introductionmentioning

confidence: 99%

Atopic eczema: burden of disease and individual suffering – results from a large EU study in adults

Ring

Zink

Arents

et al. 2019

Acad Dermatol Venereol

127

112

View full text Add to dashboard Cite

Background Atopic eczema (AE, atopic dermatitis) is one of the most common non‐communicable inflammatory skin diseases affecting 1–5% of the adult population in Europe with marked impairment in quality of life. In spite of great progress in understanding the pathophysiology of disturbed skin barrier and immune deviation, AE still represents a problem in daily clinical practice. Furthermore, the true impact of AE on individual suffering is often not recognized. Objectives With a large European study, we wanted to provide insights into the actual suffering and individual burden of disease in adult patients with AE. Methods A total of 1189 adult patients (18–87 years, 56% female) with moderate to severe AE were recruited in nine European countries by dermatologists or allergists together with the help of patient organizations. A computer‐assisted telephone interview was performed by experienced interviewers between October 2017 and March 2018. The following instruments were used to assess severity or measure quality of life: Patient‐Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HADS‐D) and a newly developed Atopic Eczema Score of Emotional Consequences (AESEC). Patients were also asked to self‐assess the severity of their disease. Results Despite current treatment, 45% of participants still had actual moderate to very severe AE in POEM. Due to their skin disease, 57% missed at least 1 day of work in the preceding year. DLQI showed moderate to extremely large impairment in 55%. According to HADS‐D, 10% scored on or above the threshold of eight points with signs of depressive symptoms. Assessed with AESEC, 57% were emotionally burdened with feelings such as ‘trying to hide the eczema’, ‘feeling guilty about eczema’, having ‘problems with intimacy’ and more. Of persons actually suffering from severe AE, 88% stated that their AE at least partly compromised their ability to face life. Conclusions This real‐life study shows that adults with a moderate to severe form of AE are suffering more than what would be deemed acceptable. There is a need for increased awareness of this problem among healthcare professionals, policymakers and the general public to support research in the development of new and more effective treatments and provide access to better and affordable health care for affected patients.

show abstract

“…The multidimensional burden of disease in North American and European AD patients is well documented. Relative to the general population, patients with AD experience increased levels of itch, pain, sleep disturbance, anxiety and depression, as well as an impaired health‐related quality of life (HRQoL) 11, 12, 13, 14, 15. In contrast, published data on the burden of AD in the Japanese patient population is limited to two relatively small studies 16, 17…”

Section: Introductionmentioning

confidence: 99%

Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey

Arima

Gupta

Gadkari

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Atopic dermatitis is a chronic inflammatory skin disease. The objective of this study was to characterize the burden of atopic dermatitis in Japanese adult patients relative to the general population. Japanese adults (≥18 years) with a self‐reported diagnosis of atopic dermatitis and adult controls without atopic dermatitis/eczema/dermatitis were identified from the 2013 Japan National Health and Wellness Survey. Atopic dermatitis patients were propensity‐score matched with non‐atopic dermatitis controls (1:2 ratio) on demographic variables. Patient‐reported outcome data on comorbidities, mood and sleep disorders, health‐related quality of life, work productivity and activity impairment, and health‐care resource utilization were analyzed in atopic dermatitis patients and matched controls. A total of 638 Japanese adult patients with atopic dermatitis were identified, of whom 290 (45.5%) rated their disease as “moderate/severe” and 348 (54.5%) as “mild”. The analysis cohort comprised 634 atopic dermatitis patients and 1268 matched controls. Atopic dermatitis patients reported a significantly higher prevalence of arthritis, asthma, nasal allergies/hay fever, anxiety, depression and sleep disorders compared with controls (all P < 0.001). Atopic dermatitis patients also reported a significantly poorer health‐related quality of life, higher overall work and activity impairment, and higher health‐care resource utilization (all P < 0.001). Self‐rated disease severity was not associated with disease burden, except for a significantly higher overall work and activity impairment. In conclusion, Japanese adult patients with atopic dermatitis reported a substantial disease burden relative to adults without atopic dermatitis, suggesting an unmet need for effective strategies targeting disease management.

show abstract

The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association

Cited by 547 publications

References 40 publications

Mesenchymal Stem Cell Therapy for Inflammatory Skin Diseases: Clinical Potential and Mode of Action

Mesenchymal Stem Cell Therapy for Inflammatory Skin Diseases: Clinical Potential and Mode of Action

Atopic eczema: burden of disease and individual suffering – results from a large EU study in adults

Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey

Contact Info

Product

Resources

About